NEW PRODUCT GALLERY

0

 

AIR OPTIX MULTIFOCAL COMBINES PRECISION AND MOISTURE
Alcon’s new AIR OPTIX plus HydraGlyde Multifocal contact lenses incorporate Precision Profile Design to offer clear, seamless vision at near, intermediate and distance. The lenses also feature lasting lens surface moisture through the HydraGlyde Moisture Matrix and deposit protection with Alcon’s unique SmartShield Technology. The new AIR OPTIX plus HydraGlyde Multifocal contact lenses will be widely available beginning Oct. 1. Go to AirOptix.com.

FDA CLEARS HEIDELBERG’S OCT ANGIOGRAPHY MODULE
Heidelberg Engineering has received clearance from the U.S. Food and Drug Administration for its OCT Angiography Module. OCTA is a noninvasive imaging technique that provides 3D visualization of perfused ocular vasculature. Combined with structural OCT and dye-based angiography, the OCTA technology is designed to give clinicians a more comprehensive understanding of ocular abnormalities. The additional module is now available for new and existing SPECTRALIS upgradeable diagnostic imaging devices. Go to HeidelbergEngineering.com.

NEW GLAUCOMA DRUG LEAVES OUT PRESERVATIVE
Sun Pharmaceutical Industries Ltd. and Sun Pharma Advanced Research Company Ltd. (SPARC) have received FDA approval of their New Drug Application for XELPROS (latanoprost 0.005%) for the reduction of elevated intraocular pressure in patients who have open-angle glaucoma or ocular hypertension. XELPROS was developed using SPARC’s proprietary Swollen Micelle Microemulsion technology, which helps solubilize drugs that otherwise have limited or no solubility. This technology eliminated the need for the preservative benzalkonium chloride, or BAK.

In randomized, controlled clinical trials of patients with open-angle glaucoma or ocular hypertension, XELPROS lowered IOP by a mean of up to 6mm Hg to 8mm Hg.

XELPROS will be commercialized in the U.S. by Sun Ophthalmics, the branded ophthalmic division of Sun Pharmaceutical Industries. Go to SunPharma.com or MyXELPROS.com.

Share.

Leave A Reply